Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs. The up-regulated genes, such as activating transcription factor 3 and myelin basic protein in oligodendrocytes or claudin 11 in type II astrocytes, might contribute to OPC differentiation and represent constitutive components of oligodendrocytes or type II astrocytes. The down-regulated genes in both oligodendrocytes and type II astrocytes, such as transcription factor 19, might be involved in maintaining self-renewal and/or represent the property of OPCs. These results provide new insights into the elucidation of the molecular mechanisms, by which OPCs differentiate to oligodendrocytes or type II astrocytes.
Oligodendrocytes (OLs) produce myelin in the central nervous system (CNS). They wrap axons of neurons to produce myelin sheaths, provide trophic support and protection for neurons and their axons. The persistent deficiency in myelin results in the disorders of the CNS, such as multiple sclerosis and spinal cord injury. Oligo dendrocytes (OLs) are generated from oligodendrocyte precursor cells (OPCs) , which arise at multiple locations in the developing brain and spinal cord and migrate throughout the CNS (Qi et al. 2002; Kessaris et al. 2006) . OPCs express specific markers, such as a cell-surface ganglioside (A2B5) that is recognized by A2B5 monoclonal antibody (Raff et al. 1983 ) and platelet-derived growth factor receptor α (PDGFRα), and they are bipotential in vitro (Raff et al. 1983; Louis et al. 1992) . OPCs can differentiate into OLs in serum-free medium or type II astrocytes in serum-containing medium when cultured in vitro (Raff et al. 1983; Louis et al. 1992) . Type II astrocytes displayed a typical process-bearing morphology and express both A2B5 and glial fibrillary acidic protein (GFAP) and may contribute to the structure of nodes of Ranvier (Ffrench-Constant and Raff 1986) . OPC transplantation into the area of demyelination may be a feasible approach to repairing CNS disorders (Chari and Blakemore 2002; Keirstead et al. 2005 ). However, due to their bipotential differentiation potential, when transplanted into lesion site, the majority of OPCs differentiate into astrocytes (Lu et al. 2010) . Therefore, it is an important issue to control the implanted OPCs to differentiate into OLs, but not astrocytes. For this purpose, the molecular mechanisms that control OPC differentiation should be well understood.
Microarray technology provides a powerful tool for large-scale gene expression studies (Hu et al. 2004) . In the present study, we cultured OPCs isolated from the spinal cords of embryonic rats at 16 days of gestation and induced them into OLs or type II astrocytes under different culture conditions, respectively. We then employed a cDNA microarray to detect differential gene expression in three cell types.
Materials and Methods

Cell Culture
OPCs were immunopanned from embryonic day 16 (E16) Wistar rat spinal cords using an A2B5 antibody and a protocol modified from previous studies (Mayer-Proschel et al. 1997; Mujtaba et al. 1999; Cao et al. 2005) . Immunopanned OPCs were plated onto Poly-D-lysine (PDL)/fibronectin-coated 10 × 12 cm culture dishes and growth medium was added and changed every other day. The growth medium contained DMEM/Ham's F12 (Invitrogen, Carlsbad, CA, USA), 1 × N2 and 1 × B27 supplements (Invitrogen), fibroblast growth factor 2 (FGF-2) (20 ng/ml; Sigma, St. Louis, MO), and platelet-derived growth factor aa (PDGF-aa) (10 ng/ml; Chemicon, Temecula, CA). After 5~7 days, the cells were passaged. In all cases, an aliquot of cells was analyzed the following day to determine the efficiency of immunopanning. Only those preparations in which >95% of the bound cells expressed A2B5 and at passage 2 (P2) were used. OLs and type II astrocytes were induced from the OPCs in the presence of thyroid hormone [tri-iodothyronine (T3)] or serum after withdrawal of bFGF and PDGF-AA according to the method described previously (Fu et al. 2007; Lu et al. 2008) . Briefly, for OL differentiation, PDGF and bFGF were withdrawn from the OPCmedium, T3 was added (30 μM). The OPCs were allowed to differentiate for 5 days. Antibodies against O1 (a marker of pre-myelinating OLs), receptor interaction protein (Rip) and myelin basic protein (MBP) were used to identify OLs. For type 2-astrocytes differentiation, OPCs were cultured in basal-OPC-medium supplemented with 10% fetal bovine serum (FBS) for 5 days. Antibodies against A2B5 and GFAP were used to identify type 2 astrocytes.
All embryonic rats were obtained from pregnant Wistar rats bred in the Animal Care Facility at Bengbu Medical College, Bengbu, P.R. China. All animal care was carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80-23; revised 1996) and was approved by the Animal Care Committee of the Use of Laboratory Animals, Bengbu Medical College.
Immunocytochemistry
For identification of cell purity, in some experiment, OPCs were plated onto PDL/fibronectin-coated coverslips in 35-mm dishes at a density of 5 × 10 4 cells/coverslip (12 mm). OPCs were cultured, and
OLs and type II astrocytes were induced from OPCs as described above. The OPCs, OLs and astrocytes cultured on coverslips were rinsed in phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde (PFA) in PBS for 20 min at room temperature (RT). After three rinses in PBS (10 min each), the cells were incubated with 10% normal goat serum (NGS) in PBS in the presence (for intracellular antigens) or absence (for surface markers) of 0.3% Triton X-100 for 1 hour at RT and then with one of the monoclonal primary antibodies against A2B5, NG2 and PDGFRα (1:100; all from Chemi con, Temecula, CA, USA), the markers for OPCs, O4 (a specific antigen on the surface of young OLs), O1, Rip and MBP (1:100; all from Chemicon), the markers for OLs, or both A2B5 and glial fibrillary acidic protein (GFAP; 1:200; Sigma, St. Louis, MO, USA), the marker for type II astrocytes overnight at 4°C. On the second day, the cultures were incubated with rhodamine-or fluorescein isothiocyanate (FITC)-conjugated secondary antibody (all from Jackson ImmunoResearch Lab, West Grove, PA, USA) for 1 hour at 37°C. After staining, the coverslips were rinsed and mounted with Gel/ Mount aqueous mounting media (Biomeda Corp., Foster City, CA, USA) containing Hoechst 33342, a fluorescent nuclear dye (1 μg/ml; Sigma). The coverslips were examined using an Olympus BX60 microscope. For cell counts, at least five randomly selected fields with a total of more than 500 cells were counted. In all experiments, primary antibody omission controls were used to confirm the specificity of the immunofluorescence labeling.
RNA Isolation and Hybridization to Affymetrix GeneChips
OPCs, differentiated OLs and type II astrocytes (5 days) derived from three rats were used in cDNA microarray detection. Purified cells were rinsed twice with PBS and total RNA was extracted using SV total RNA isolation system (Promega, Madison, USA) according to the manufacturer's instruction. RNA was treated with DNase I (Promega) to eliminate genomic DNA contamination. The integrity and purification of RNA samples were monitored by formaldehyde/ agarose gel electrophoresis. The concentration of RNA was determined by repeated OD measurements of aliquots at wavelength of 260 nm.
The microarray hybridization analysis was performed by Biochip Co., Ltd. (Shanghai, China) according to the manufacturer's protocol (Affymetrix, Santa Clara, CA, USA). Biotinylated cRNA samples were prepared according to the standard Enzo Bioarray TM protocol (Enzo Life Sciences, Farmingdale, NY, USA). In brief, total RNA (1 μg) from each sample was converted to double-stranded cDNA with the Bioarray TM Single-Round RNA Amplification and Labeling Kit (Enzo Life Sciences). After second-strand synthesis, the cDNA was purified with the cDNA Purification Kit (Enzo Life Sciences). The resulting double-stranded DNA was then used to generate multiple copies of biotinylated cRNA by in vitro transcription with the Bioarray HighYield RNA Transcript Labeling Kit (Enzo Life Sciences). For each sample, biotinylated cRNA (10 μg) spiked with bioB, bioC, bioD, and cre (Hybridization Control) was hybridized to an Affymetrix Rat 230 2.0 Microarray for 16 h at 45°C. Following hybridization, all arrays were washed and stained in an Affymetrix Gene-Chip Fluidics Station. Stained arrays were scanned with an Affymetrix GeneChip1 Scanner 3000. Quality checks and data analyses were carried out using Affymetrix GeneChip Operating Software and Expression Console. All microarray data reported in the manuscript are described in accordance with MIAME guidelines. The processed image file of the Affymetrix Rat 230 2.0 array contains over 31,000 probe sets representing ~28,700 well-substantiated rat genes. The probe set level data were analyzed with either Rosetta Resolver Gene Expression Data Analysis System (Rosetta, Seattle, WA, USA) or Partek Genomics Suite, version 6.4, build 6.09.0129 (Partek, St. Louis, MO, USA). The fold change was presented as mean ± S.E.M of the ratio value (n = 3). We used a combination of 4-fold change in signal intensity and p < 0.05 as criteria to consider whether the differential expression of a gene was significant.
Real-time RT-PCR
cDNA from 5 μg of total RNA was synthesized using Avian myeloblastosis virus (AMV) reverse transcriptase (Takara, Japan 
Results
Identification of OPCs, OLs and type II astrocytes
OPCs isolated and cultured for this study were identified by morphological and immunocytochemical analyses using following antibodies: NG2, A2B5, PDGFRa, O4, Rip, GFAP and βIII-tubulin. OPCs displayed typical bipolar or tripolar morphology (Fig. 1A) and expressed the markers for OPCs including PDGFR ( Fig. 1B, E; 95.36 ± 4.59%), NG2 ( Fig. 1C, E ; 94.63 ± 3.37%) and A2B5 ( Fig. 1D, E ; 96.35 ± 3.95%). In addition, a small percentage (4.86 ± 0.89%) of O4 expressing cells and a smaller percentage of GFAP (only 2.81 ± 1.4%) expressing cells were detected (Fig.1E) . These data suggest that OPCs obtained were highly purified. To obtain the differentiated OLs and type II astrocytes, parallel OPC cultures were maintained in T3-or 10% FBS-containing basal-OPC-medium (without PDGF-AA and bFGF), repectively. In the presence of T3, OPCs readily differentiated into O1 ( Fig. 2A, D; 78.36 ± 4.37%), Rip ( Fig. 2B, D; 95.36 ± 2.37%) and MBP-positive cells ( Fig. 2C, D; 79.28 ± 5.48%). The majority of them displayed typical highly branched morphology of OLs. In the presence of 10% FBS, over 95% of the cells were flattened with multiple processes and positive for both A2B5 and GFAP (Fig. 2E-H ). These cells were morphologically and immunocytochemically type II astrocytes. No neurons were observed under these differentiating conditions. These results suggest that OPCs, OLs and type II astrocytes prepared here were three distinct cell populations with high purity and unique phenotypic characteristics, and thus could be readily used to detect differential gene expression among the three cell populations.
Generation of a comprehensive database of gene expression and verification of the results
To identify the detailed program of OPC differentiation towards OLs or type II astrocytes and biological characteristics of three cell populations, we analyzed the global gene expression changes between them using Affymetrix Rat 230 2.0 array. Four-fold change in signal intensity and p < 0.05 were used as the criteria of the significant differential expression of a given gene. Genes with changed expression in every spot were defined as the commonly upregulated or down-regulated genes. Of these, 192 genes had a significant change in expression in OLs compared with OPCs (83 up-regulated and 89 down-regulated), and 178 in type II astrocytes compared with OPCs (92 up-regulated and 86 down-regulated).
To examine the reliability of our microarray data, we selected randomly 15 up-regulated genes or down-regulated genes, and investigated their expression levels by real-time RT-PCR in the same RNA samples that had been used for microarray analysis. The results of real-time RT-PCR were consistent with those from the cDNA microarray data in 14 of the 15 genes (Fig. 3) .
Differential gene expression between OPCs and OLs
To learn more about differentiation and property of OLs, we analysis gene expression profiles of OPCs and OLs which were differentiated from OPCs in the presence of T3. Both up-regulated and down-regulated genes exceeding 4 folds in OLs were listed in Tables 1 and 2 , respectively. Based on the potential function of these genes, we categorized them into several classes which 
Differential gene expression between OPCs and Astrocytes
Similarly, gene expression profiles of OPCs and type II astrocytes which differentiated from OPCs in the presence of 10% serum were analyzed. Both up-regulated and down-regulated genes exceeding 4 folds in type II astrocytes were listed in Tables 3 and 4 , respectively. There were also some significantly changed genes in seruminduced type II astrocyte differentiation, such as erythropoietin receptor (EPOR), prostaglandin F receptor (PTGFR), galanin receptor 2 (GALR2), platelet-derived growth factor receptor-like (PDGFRL), metadherin (MTDH)/astrocyte elevated gene 1 (AEG-1), THBS1, myocilin, BMPs, and Noggin.
Discussion
In the present report, the differential gene expression profiling in OPCs, OLs and type II astrocytes were studied. OPCs were obtained from E16 Wistar rats and were induced into OLs and type II astrocytes in the presence of T3 or 10% serum in vitro, respectively. Immunocytochemistry results demonstrated that OPCs, OLs and type II astrocytes were characteristic and highly pure. Subsequently, using the Affymetrix Rat 230 2.0 array, the differential gene expression profiling in the three cell populations were identified. Among these genes, some may participate in OPC differentiation and others may constitute molecular identity of each cell population.
Gene profiles of OPCs
In the present study, we found that many genes were down-regulated in expression after OPCs differentiated into OLs and/or type II astrocytes. Among these down-regulated genes, some might be involved in maintaining selfrenewal of OPCs and/or represent the property of OPCs. Ligand-receptor interaction plays a determining role in many cell biological processes. It is the first step for growth factors, cytokines and other regulatory elements to mediate cell responses, such as proliferation, differentiation, migration, angiogenesis, immune responses and cell death (Vermeer and Leuven 1990; Jones et al. 2008) . Our results showed that a number of receptor genes were downregulated in expression after OPCs differentiated into OLs or type II astrocytes. Hyaluronan-mediated motility receptor (HAMMR) is first described by Turley (1982) . It can bind hyaluronan, ERK kinase and microtubules and participates in cell motility, signaling, and oncogenic events (Maxwell et al. 2005) . It has been reported that hyaluronan, one of the ligands of HAMMR, accumulates in demyelinated lesions and inhibits OPC maturation through binding to CD44, another receptor of hyaluronan (Back et al. 2005) . The high expression of HAMMR on OPCs implicated that HAMMR might be another CD44-like receptor which can mediate hyaluronan to maintain self-renewal of OPCs. Our previous study demonstrated that platelet derived growth factor receptor alpha polypeptide (PDGFRα) is differentially expressed (12-fold) during the induction from NSCs to OPCs (Hu et al. 2004) . Further study showed that PDGF-AA plays a dual role in mediating the number of OL lineage cells: an early instruction of OPC differentiation from NSCs and later proliferation of committed OPCs (Hu et al. 2008) . In the present study, we found that PDGFRα was strongly down-regulated in both OLs and type II astrocytes, suggesting that PDGFRα is also a key factor in maintaining self-renewal and inhibiting differentiation of OPCs. Transcription factors (TFs) and binding proteins play prominent roles in developmental processes and cell-lineage specification (Ahmed et al. 2009; Burrows et al. 2010) . Here, we found that many OPC-expressed TFs and binding proteins, such as E2F transcription factor 8, pituitary tumortransforming 1 and cell division cycle 20 homolog, were down-regulated in both OLs and type II astrocytes, suggesting they may be involved in maintaining proliferation and self-renewal of OPCs.
Candidate genes that may intrinsically control OL-specific differentiation and/or represent the property of OLs
As shown in Table 1 , some genes were up-regulated in OLs compared with OPCs. Among them, several genes which encode structural constituent of myelin sheath were up-regulated markedly, including myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOgP), myelin-associated glycoprotein (MAG), myelin protein zero-like 1 (Mpzl1), peripheral myelin protein 22 (PMP22), proteolipid protein (PLP), tenascin R (TNR), and tetraspanin 2 (Tspan2). These well-understood genes (David and Lacroix 2003) were confirmed again to highly express in OLs, but not type II astrocytes, suggesting that they indeed represent the unique characteristic of mature OLs.
It has been reported that transferrin (Tf), the iron transport glycoprotein in biological fluids of vertebrates, can be synthesized by OLs. The Tf can selectively regulate MBP expression at the transcriptional level and increase the differentiation, maturation and myelination of OLs (EspinosaJeffrey et al. 2002; Sow et al. 2006) . Thus, our finding that high expression of Tf in OLs is consistent with previous report. In our previous study, we have shown that there was a 3-fold increase in ApoD expression in OLs as compared to NSCs (Hu et al. 2004) . Here, ApoD expression in Ols was found increasing more than 4-fold (but not type II astrocytes) as compared to OPCs. Further increased expression of ApoD in OLs indicates that more lipid transport is necessary in the progress of maturation of OLs. Bone mor-phogenetic proteins (BMPs) influence the lineage commitment of embryonic neural stem cell progeny by promoting astroglial lineage determination (Gross et al. 1996) and inhibiting oligodendroglial differentiation (Samanta and Kessler 2004) . Here, we showed that BMP4 had an increased expression in oligodendrocytes, but didn't change in type II astrocytes, which is consistent with Kondo's report (Kondo and Raff 2004) . Besides above-mentioned genes, there are still many other genes with increasedexpression in OLs. Among these genes, it is possible that certain genes are involved in differentiation of OLs and/or represent the property of OLs. Further functional research of some candidate genes remains to be clarified.
Candidate genes that may contribute to type II astrocyte fate and/or represent the property of type II astrocytes
Our results showed that a number of receptor genes were increased in expression when OPCs differentiated into type II astrocytes. Among these up-regulated genes, some of them might contribute to OPC differentiation into type II astrocytes. Erythropoietin (EPO), a hematopoietic growth factor that stimulates proliferation and differentiation of erythroid precursor cells, is also known to exert neurotrophic activity in the CNS (Sugawa et al. 2002) . EPO mRNA expression was demonstrated only in human astrocytes, while EPOR expression was found in human neurons, astrocytes, and microglia. Neither EPO nor EPOR expression was found in OLs (Nagai et al. 2001; Sugawa et al. 2002) . These reports are consistent with our present result which show an over 18-fold up-regulation of EPOR gene expression in type II astrocytes, but not OLs. Therefore, we suspect that EpoR maybe a mediator of proliferation of astrocytes as has been reported (Nagai et al. 2001; Sugawa et al. 2002) . Moreover, it is also possible that high expression of EpoR contributes to differentiation of type II astrocytes from OPCs. Another receptor, prostaglandin F receptor (PTGFR), was also found high expression in type II astrocytes. It has been reported that PTGFR signalling regulates endothelial cell network formation and proliferation (Keightley et al. 2010) . Whether PTGFR also play a role in type II astrocyte differentiation should be clarified in the future. Two other receptors, galanin receptor 2 (GALR2) and platelet-derived growth factor receptor-like (PDGFRL), which have been shown increased gene-expression in type II astrocytes are also need to be further investigated. Metadherin (MTDH) was originally reported as a novel late response gene, which can be induced to express in human fetal astrocytes after HIV-1 infection or treatment with viral glycoprotein gp120 or TNF-α. Thus, MTDH is also named astrocyte elevated gene 1 (AEG-1) (Su et al. 2002) . It has been reported that Metadherin acts in several crucial aspects of tumor progression, including transformation, evasion of apoptosis, invasion, metastasis and chemoresistance. MTDH may also activate Akt and affect a number of additional Akt downstream signaling molecules that are crucial for cellular proliferation and survival (Hu et al. 2009 ). In this study, we found a very high expression of MTDH in type II astrocytes (34-fold of OPCs). Thus, MTDH/AEG-1 may play an important role in differentiation of type II astrocytes. THBS1 played diverse roles in the latter stage of tumorigenesis, which may function as an adhesive protein or a modulator of extracellular proteases to promote tumor invasion (Kazerounian et al. 2008) . In the present study, the observation of THBS1 gene-expression in type II astrocytes indicates that THBS1 may transduce a growth-regulatory signal in these cells. Myocilin was the first molecule discovered to be linked with primary open angle glaucoma (POAG), a blinding disease characterized by progressive loss of retinal ganglion cells. It was reported that optic nerve head astrocytes constitutively express myocilin in vivo (Noda et al. 2000; Ricard et al. 2001) . In the present study, a 5-fold increase in Myocilin gene-expression was found in type II astrocytes as compared to OPCs, confirming the previous finding. Noggin is the antagonist of BMPs and inhibits astroglial differentiation induced by BMPs. In the present study, our result showed over 8-fold increase in Noggin expression in type II astrocytes. This is similar to the previous report which found a strong expression of Noggin in astrocytes in the developing optic nerve (Kondo and Raff 2004) .
In summary, using cDNA microarray technology, we have identified differentially expressed genes during the differentiation of OPCs into OLs or type II astrocytes. Among them, the up-regulated genes might contribute to OPC differentiation and represent constitutive components of OLs or type II astrocytes, whereas the down-regulated genes might be involved in maintaining self-renewal and/or represent the property of OPCs. Results of this study contribute to elucidation of molecular differences between OPCs and OLs or type II astrocytes and provide new insights into mechanism of OPC differentiation.
